Microbot Medical Inc.
175 Derby St., 27/1
About Microbot Medical Inc.Microbot was founded in 2010 and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
Founders: Harel Gadot, Moshe Shoham, Yossi Bornstein
CEO: Harel Gadot
COO: Hezi Himelfarb
CFO: David Ben Naim
FOLLOW MICROBOT MEDICAL:
Tweets by Microbot
36 articles with Microbot Medical Inc.
Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board
Microbot Medical Inc. continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board.
Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowance
Global patent jurisdictions continue to recognize Microbot Medical Inc.’s innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance.
Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology
Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions.
Microbot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt
Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data, the FDA’s feedback will allow the Company to apply for a limited clinical investigation known as an Early Feasibility Study (EFS), which is designed for novel technologies such as the SCS. Consequently, the Company rei
Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional RadiologistsScientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders
Microbot Medical Inc. continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board members: Stephen B. Solomon, MD, a board-certified radiologist with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K.
Microbot Medical Demonstrates Significant Progress in 2020; Outlines Anticipated Milestones for 2021
Microbot Medical Inc. has concluded 2020 with the achievement of several operating and developmental milestones.
Microbot Medical Inc. announced that it has received patents in multiple jurisdictions, further demonstrating the Company’s continued execution of expanding and protecting its Intellectual Property portfolio.
Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference
Microbot Medical Inc. announced that Harel Gadot, the Company’s CEO, President and Chairman, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 6th Annual Israel Conference, on November 12, 2020 at 2:00pm ET.
Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis
Microbot Medical Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application No. 15/592,227, which pertains to a device for reducing dialysis shunt stenosis.
Microbot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement Webinar to be Held on Wednesday August 26th at 11am ET
Following its participation at the Needham Virtual Med Tech & Diagnostic conference, as well as the overwhelming interest generated since its recent announcement which included the outcome of a feasibility animal study with respect to the LIBERTYTM Robotic System, Microbot Medical Inc.
World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical Staff
Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic SystemResults to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference
At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using the Company’s LIBERTY Robotic System.
Microbot Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of DirectorsVascular Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System
Microbot Medical Inc. has further strengthened the Company’s capabilities and expertise as Mr. Tal Wenderow, an experienced medical device and robotics executive with a proven track record in small and mid-size companies, has been appointed to the Company's Board of Directors.
Microbot Medical Appoints Aileen Stockburger to the Board of DirectorsProven Track Record of Numerous M&A and Strategic Collaboration Transactions
Microbot Medical Inc. announced the appointment of Aileen Stockburger to the Company's Board of Directors, effective April 1, 2020.
Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, effective immediately. In his new role, Dr. Morag will lead the development and execution of the clinical strategy of the Company’s technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline.
Microbot Medical Inc., announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, commencing June 2020.
Microbot Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning Shunt
Microbot Medical Inc. has received an official communication from the European Patent Office regarding its intention to grant European Patent Application No. 11795301, covering the Company’s Self-Cleaning Shunt.
Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 952,383 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $10.0 million, before deducting placement agent fees and offering expenses.
Microbot Medical Inc. Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Microbot Medical Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 900,901 shares of its common stock, at a purchase price per share of $11.10, priced at-the-market under Nasdaq rules.
Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million, before deducting placement agent fees and offering expenses.